Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

opicapone

- PMLiVE

Roche to boost US footprint with $50bn investment over next five years

The commitment is aimed at bolstering the company’s pharmaceutical and diagnostics divisions

- PMLiVE

Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

The collaboration will leverage Repertoire’s immune mapping DECODE platform

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

- PMLiVE

Roche’s Columvi granted EC approval to treat diffuse large B-cell lymphoma

Approximately 38,000 people are diagnosed with DLBCL every year in Europe

- PMLiVE

Johnson & Johnson’s subcutaneous Rybrevant granted EC approval to treat NSCLC

It is hoped that the formulation will improve the treatment experience for patients

- PMLiVE

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

- PMLiVE

AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

Approximately 25% of cases are diagnosed during childhood or adolescence

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

EU flag

Genmab announces EC approval of Tivdak in recurrent or metastatic cervical cancer

Approximately 660,000 new cases of the disease were diagnosed globally in 2022 alone

- PMLiVE

Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links